Aktienbewertung
Konkurrenz
| Unternehmen | Börsenwert | G | R | O | W | T | H |
|---|---|---|---|---|---|---|---|
|
Eli Lilly and NYSE:LLY |
664,39 Mrd. $ | 15,90 % | 6/6 | 51,27 % | -11,74 % | 31,41 % | UP |
|
Sanofi ENXTPA:SAN |
104,18 Mrd. € | 3,03 % | 5/6 | 10,94 % | 10,62 % | 32,72 % | DOWN |
|
Bristol-Myers Squibb NYSE:BMY |
93,57 Mrd. $ | 0,21 % | 5/6 | 59,64 % | 15,41 % | 19,62 % | DOWN |
|
Teva Pharmaceutical Industries NYSE:TEVA |
19,30 Mrd. $ | -0,24 % | 4/6 | 2,27 % | -72,89 % | 36,66 % | UP |
|
Intra-Cellular Therapies NasdaqGM:ITCI |
14,02 Mrd. $ | 488,48 % | 4/6 | 40,71 % | 10,65 % | 0,00 % | UP |
|
Eisai TSE:4523 |
1.183,93 Mrd. ¥ | -9,74 % | 2/6 | 1,29 % | 36,24 % | 2,38 % | DOWN |
|
Alkermes NasdaqGS:ALKS |
4,61 Mrd. $ | 21,70 % | 4/6 | -33,87 % | 40,63 % | 50,38 % | DOWN |
|
Sumitomo Pharma TSE:4506 |
451,72 Mrd. ¥ | -6,60 % | 1/6 | 35,31 % | -72,92 % | -37,59 % | UP |
|
MedinCell ENXTPA:MEDCL |
0,58 Mrd. € | 43,88 % | 5/6 | 46,48 % | -4,08 % | 26,44 % | UP |
